TuHURA Biosciences (HURA) 10-Q 13 May 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2020	May 12, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	DelMar Pharmaceuticals, Inc.
Entity Central Index Key	0001498382
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		11,429,228
Entity File Number	001-37823
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Mar. 31, 2020	Jun. 30, 2019
Current assets
Cash and cash equivalents	$ 4,973,378	$ 3,718,758
Prepaid expenses and deposits	114,865	280,248
Interest, taxes and other receivables	10,339	26,187
Current assets	5,098,582	4,025,193
Intangible assets - net	3,659	12,062
Total assets	5,102,241	4,037,255
Current liabilities
Accounts payable and accrued liabilities	1,085,571	1,744,517
Related party payables	296,184	325,208
Total liabilities	1,381,755	2,069,725
Stockholders' equity
1 special voting share at March 31, 2020 (June 30, 2019 - 1)
Common stock Authorized 95,000,000 shares at March 31, 2020 and June 30, 2019, $0.001 par value 11,427,132 issued at March 31, 2020 (June 30, 2019 - 3,839,358)	11,427	3,839
Additional paid-in capital	56,395,453	50,954,741
Warrants	8,382,588	6,588,283
Accumulated deficit	(65,893,587)	(60,578,345)
Accumulated other comprehensive income	21,178	21,178
Total stockholders' equity	3,720,486	1,967,530
Total liabilities and stockholders' equity	5,102,241	4,037,255
Preferred Stock Series A
Stockholders' equity
Preferred stock	278,530	278,530
Preferred Stock Series B
Stockholders' equity
Preferred stock	$ 4,524,897	$ 4,699,304

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Jun. 30, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock special voting shares issued	1	1
Common stock, shares authorized	95,000,000	95,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	11,427,132	3,839,358
Series A Preferred Stock
Preferred Stock, shares issued	278,530	278,530
Preferred stock, shares outstanding	278,530	278,530
Series B Preferred Stock
Preferred Stock, shares issued	648,613	673,613
Preferred stock, shares outstanding	648,613	673,613

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Expenses
Research and development	$ 898,720	$ 735,844	$ 2,332,388	$ 2,702,213
General and administrative	1,077,642	935,530	3,045,017	2,796,884
Operating expenses	1,976,362	1,671,374	5,377,405	5,499,097
Other (income) loss
Change in fair value of derivative liability		189		(852)
Foreign exchange (gain) loss	(2,416)	5,819	(536)	16,754
Interest income	(16,964)	(13,397)	(73,965)	(49,513)
Other loss (income)	(19,380)	(7,389)	(74,501)	(33,611)
Net loss for the period	1,956,982	1,663,985	5,302,904	5,465,486
Computation of basic loss per share
Net loss for the period	1,956,982	1,663,985	5,302,904	5,465,486
Series B Preferred stock dividend	1,473	23,202	6,071	75,477
Net loss for the period attributable to common stockholders	$ 1,958,455	$ 1,687,187	$ 5,308,975	$ 5,540,963
Basic and fully diluted loss per share	$ 0.17	$ 0.67	$ 0.52	$ 2.27
Basic and fully diluted number of shares	11,417,456	2,518,452	10,116,541	2,444,065

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders' Equity (Unaudited) - USD ($)	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Warrants	Accumulated deficit	Total
Beginning Balance at Jun. 30, 2018	$ 2,297	$ 43,198,193	$ 21,178	$ 6,425,410	$ 8,229,482	$ (52,441,337)	$ 5,435,223
Beginning Balance, shares at Jun. 30, 2018	2,296,667
Warrants issued for services					30,661		30,661
Shares issued for services	$ 1	4,138					4,139
Shares issued for services, shares	706
Performance stock unit expense		61,514					61,514
Stock option expense		132,902					132,902
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 4	36,081				(36,085)
Series B preferred stock dividend, shares	4,960
Loss for the Period						(1,991,804)	(1,991,804)
Ending Balance at Sep. 30, 2018	$ 2,302	43,432,828	21,178	6,425,410	8,260,143	(54,471,315)	3,670,546
Ending Balance, shares at Sep. 30, 2018	2,302,333
Exercise of warrants for cash	$ 297	2,936,881			(2,210,697)		726,481
Exercise of warrants for cash, Shares	296,667
Conversion of Series B preferred stock to common stock	$ 10	279,041		(279,051)
Conversion of Series B preferred stock to common stock, shares	10,000
Warrants issued for services					(2,859)		(2,859)
Shares issued for services		2,617					2,617
Shares issued for services, shares	607
Performance stock unit expense		61,514					61,514
Stock option expense		122,751					122,751
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 5	16,185				(16,190)
Series B preferred stock dividend, shares	4,735
Loss for the Period						(1,809,697)	(1,809,697)
Ending Balance at Dec. 31, 2018	$ 2,614	46,851,817	21,178	6,146,359	6,046,587	(56,299,291)	2,769,264
Ending Balance, shares at Dec. 31, 2018	2,614,342
Exercise and exchange of warrants - issue costs		(16,186)					(16,186)
Warrants issued for services					8,732		8,732
Shares issued for services	$ 1	3,512					3,513
Shares issued for services, shares	956
Performance stock unit expense		60,177					60,177
Stock option expense		99,735					99,735
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 5	23,197				(23,202)
Series B preferred stock dividend, shares	4,735
Loss for the Period						(1,663,985)	(1,663,985)
Ending Balance at Mar. 31, 2019	$ 2,620	47,022,252	21,178	6,146,359	6,055,319	(57,988,567)	1,259,161
Ending Balance, shares at Mar. 31, 2019	2,620,033
Beginning Balance at Jun. 30, 2019	$ 3,839	50,954,741	21,178	4,977,834	6,588,283	(60,578,345)	1,967,530
Beginning Balance, shares at Jun. 30, 2019	3,839,358
Issuance of shares and warrants - net of issue costs	$ 4,895	2,489,251			4,088,820		6,582,966
Issuance of shares and warrants - net of issue costs, shares	4,895,000
Exercise of warrants for cash	$ 2,655	2,421,830			(2,397,935)		26,550
Exercise of warrants for cash, Shares	2,655,000
Conversion of Series B preferred stock to common stock	$ 6	174,401		(174,407)
Conversion of Series B preferred stock to common stock, shares	6,250
Shares issued for services	$ 7	4,836					4,843
Shares issued for services, shares	6,925
Stock option expense		50,985					50,985
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 4	2,042				(2,046)
Series B preferred stock dividend, shares	3,700
Loss for the Period						(1,605,871)	(1,605,871)
Ending Balance at Sep. 30, 2019	$ 11,406	56,098,086	21,178	4,803,427	8,279,168	(62,188,351)	7,024,914
Ending Balance, shares at Sep. 30, 2019	11,406,233
Warrants issued for services					34,672		34,672
Shares issued for services	$ 5	3,339					3,344
Shares issued for services, shares	4,747
Stock option expense		159,852					159,852
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 4	2,548				(2,552)
Series B preferred stock dividend, shares	3,700
Loss for the Period						(1,740,051)	(1,740,051)
Ending Balance at Dec. 31, 2019	$ 11,415	56,263,825	21,178	4,803,427	8,313,840	(63,933,043)	5,480,642
Ending Balance, shares at Dec. 31, 2019	11,414,680
Warrants issued for services					98,625		98,625
Shares issued for services	$ 8	4,091					4,099
Shares issued for services, shares	8,752
Warrants expired		29,877			(29,877)
Stock option expense		96,191					96,191
Series A preferred cash dividend						(2,089)	(2,089)
Series B preferred stock dividend	$ 4	1,469				(1,473)
Series B preferred stock dividend, shares	3,700
Loss for the Period						(1,956,982)	(1,956,982)
Ending Balance at Mar. 31, 2020	$ 11,427	$ 56,395,453	$ 21,178	$ 4,803,427	$ 8,382,588	$ (65,893,587)	$ 3,720,486
Ending Balance, shares at Mar. 31, 2020	11,427,132

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Loss for the period	$ (5,302,904)	$ (5,465,486)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets	8,403	13,548
Change in fair value of derivative liability		(852)
Warrants issued for services	133,297	36,534
Shares issued for services	12,286	10,269
Performance stock unit expense		183,205
Stock option expense	307,028	355,388
Changes in operating assets and liabilities
Prepaid expenses and deposits	165,383	794,859
Interest, taxes and other receivables	15,848	30,433
Accounts payable and accrued liabilities	(658,946)	(425,383)
Related party payables	(29,024)	(47,189)
Net cash used in operating activities	(5,348,629)	(4,514,674)
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	6,582,966
Net proceeds from the exercise of warrants	26,550	726,179
Series A preferred stock dividend	(6,267)	(6,267)
Deferred financing costs		(25,000)
Net cash provided by financing activities	6,603,249	694,912
Increase (decrease) in cash and cash equivalents	1,254,620	(3,819,762)
Cash and cash equivalents - beginning of period	3,718,758	5,971,995
Cash and cash equivalents - end of period	$ 4,973,378	$ 2,152,233

Nature of Operations, Corporate

Nature of Operations, Corporate History, and Going Concern	9 Months Ended
	Mar. 31, 2020
Going Concern Nature of Operations and Corporate History [Abstract]
Nature of operations, corporate history, and going concern	1 Nature of operations, corporate history, and going concern Nature of operations DelMar Pharmaceuticals, Inc. (the "Company") is a clinical stage drug development company with a focus on the treatment of solid tumor cancers. The Company is currently conducting two phase 2 clinical trials in the United States and China with its product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme, the most common and aggressive form of brain cancer. Historical research indicates that VAL-083 is also active in other solid tumor cancers such as ovarian, lung, pediatric brain cancer, as well as other solid tumors of the central nervous system. The Company may pursue opportunities in these cancers in the future. In order to accelerate the Company's development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidate. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the "Exchange Agreement"), with Del Mar Pharmaceuticals (BC) Ltd. ("Del Mar (BC)"), 0959454 B.C. Ltd. ("Callco"), and 0959456 B.C. Ltd. ("Exchangeco") and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the "Reverse Acquisition"). DelMar Pharmaceuticals, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation incorporated on April 6, 2010, which is a clinical stage company with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. References to the Company refer to the Company and its wholly-owned subsidiaries, Del Mar (BC), Callco and Exchangeco. Going concern These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the nine months ended March 31, 2020, the Company reported a loss of $5,302,904, and a negative cash flow from operations of $5,348,629. The Company had an accumulated deficit of $65,893,587 and had cash and cash equivalents of $4,973,378 as of March 31, 2020. The Company is in the development stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidate is commercialized, or partnered, which may not ever occur. In the near future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company's ability to continue as a going concern within one year from the date of filing of these condensed consolidated financial statements. Consequently, management is pursuing various financing alternatives to fund the Company's operations so it can continue as a going concern. However, the coronavirus ("COVID-19") pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements but the The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development program based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Reverse stock split On May 7, 2019, the Company filed a Certificate of Change with the Secretary of State of Nevada that effected a 1-for-10 (1:10) reverse stock split of its common stock, par value $0.001 per share, which became effective on May 8, 2019. Pursuant to the Certificate of Change, the Company's authorized common stock was decreased in the same proportion as the split resulting in a decrease from 70,000,000 authorized shares of common stock to 7,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these condensed consolidated interim financial statements give retroactive effect to the 1-for-10 reverse stock split. The Company's authorized and issued preferred stock was not affected by the split. Amended articles of incorporation On June 26, 2019, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 7,000,000 to 95,000,000 shares. Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Del Mar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements of the Company as of, and for the fiscal year ended, June 30, 2019 included in the Form 10-K filed with the SEC on September 9, 2019. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three and nine months ended March 31, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2020, or for any other future annual or interim period. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements. Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company's objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company's clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the three and nine months ended March 31, 2020 and 2019, there were no material adjustments to the Company's prior period estimates of accrued expenses for clinical trials. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2020 and 2019 diluted loss per share does not differ from basic loss per share since the effect of the Company's warrants, stock options, performance stock units, and convertible preferred shares is anti-dilutive. As of March 31, 2020, potential common shares of 10,209,456 (2019 – 862,502) related to outstanding warrants, 778,750 (2019 – 292,683) relating to stock options, nil (2019 – 120,000) relating to performance stock units, and 162,177 (2019 – 210,279) relating to outstanding Series B convertible preferred shares were excluded from the calculation of net loss per common share. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Recently adopted Accounting Standard Update ("ASU") 2016-02 — Leases (Topic 842) The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of ASU 2016-02 did not have a material impact on the Company's results of operations or financial results. ASU 2018-07 — Stock Compensation (Topic 718) Improvements to Nonemployee Shares-based Payment Accounting The amendments in this update are intended to the reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees. The ASU expands the scope of Topic 718, Compensation —Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to nonemployees for goods and services. The existing guidance on nonemployee share-based payments is significantly different from current guidance for employee share-based payments. This ASU expands the scope of the employee share-based payments guidance to include share-based payments issued to nonemployees. By doing so, the FASB improves the accounting of nonemployee share-based payments issued to acquire goods and services used in its own operations. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of ASU 2018-07 did not have a material impact on the Company's results of operations or financial results. Not yet adopted ASU 2017-11 — I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non-public Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception The amendments in this update are intended to reduce the complexity associated with the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the indefinite deferral of certain provisions of Topic 480 have been re-characterized to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company has not yet evaluated the impact of adoption of this ASU on its condensed consolidated interim financial statements and related disclosures. During the nine months ended March 31, 2020, other than ASU 2017-11, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company's condensed consolidated interim financial statements.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2020
Valent Technologies LLC Agreements [Abstract]
Related party transactions	3 Related party transactions The Series A Preferred Stock is held by Valent Technologies, LLC ("Valent"), an entity owned by Dr. Dennis Brown, the Company's Chief Scientific Officer. Therefore, Valent is a related party to the Company. For the three months ended March 31, 2020 and 2019 respectively, the Company recorded $2,089 related to the dividend payable to Valent on the Series A Preferred Stock and for the nine months ended March 31, 2020 and 2019 respectively, the Company recorded $6,267 related to the dividend (note 5). The dividends have been recorded as a direct increase in accumulated deficit.

Derivative Liability

Derivative Liability	9 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liability	4 Derivative liability The Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes in fair value recorded in the condensed consolidated interim statement of operations. The derivative liabilities balance was zero at March 31, 2020 and June 30, 2019. The derivative liabilities balance consisted of 2,180 agent warrants at March 31, 2020 and June 30, 2019. Changes in the Company's derivative liability are summarized as follows: Three months ended March 31, 2020 2019 $ $ Opening balance - 76 Change in fair value of warrants - 189 Closing balance - 265 Less current portion - - Long term portion - 265 Nine months ended March 31, 2020 2019 $ $ Opening balance - 1,117 Change in fair value of warrants - (852 ) Closing balance - 265 Less current portion - - Long term portion - 265

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' equity	5 Stockholders' equity Series B Preferred stock Series B Preferred Stock 2020 Number of shares $ Balance – June 30, 2019 673,613 4,699,304 Conversion of Series B Preferred stock to common stock (25,000 ) (174,407 ) Balance – March 31, 2020 648,613 4,524,897 During the year ended June 30, 2016, the Company issued an aggregate of 902,238 shares of Series B Preferred Stock at a purchase price of $8.00 per share. Each share of Series B Preferred Stock is convertible into 0.25 shares of common stock equating to a conversion price of $32.00 (the "Conversion Price") and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $80.00, or five years from the respective final closing dates. The holders of the Series B Preferred Stock are entitled to an annual cumulative, in arrears, dividend at the rate of 9% payable quarterly. The 9% dividend accrues quarterly commencing on the date of issue and is payable quarterly on June 30, September 30, December 31, and March 31 of each year commencing on June 30, 2016. Dividends are payable solely by delivery of shares of common stock, in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the Conversion Price. The Series B Preferred Stock does not contain any repricing features. Each share of Series B Preferred Stock entitles its holder to vote with the common stock on an as-converted basis. The Series B Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company's common stock and (ii) senior to the Special Voting Preferred Stock and (iii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series B Preferred Stock. The Series B Preferred Stock shall be pari passu in liquidation to the Company's Series A Preferred Stock. The liquidation value of the Series B Preferred Stock at March 31, 2020 is the stated value of $5,188,904 (June 30, 2019 - $5,388,904). In addition, the Company and the holders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B Preferred Stock, in aggregate, a low, single-digit royalty based on their pro rata ownership of the Series B Preferred Stock on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the "Royalty Agreement"). Upon conversion of a holder's Series B Preferred Stock to common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon which vesting dates such royalty amounts shall become vested royalties. Pursuant to the Series B Preferred Stock dividend, during the three months ended March 31, 2020, the Company issued 3,700 (2019 – 4,735) shares of common stock for an amount of $1,473 (2019 – $23,202) and during the nine months ended March 31, 2020, the Company issued 11,100 (2019 – 14,430) shares of common stock for an amount of $6,071 (2019 – $75,477). These dividends have been recognized as a direct increase in accumulated deficit. A total of 648,613 (2019 – 841,113) shares of Series B Preferred Stock are outstanding as of March 31, 2020, such that a total of 162,177 (2019 – 210,279) shares of common stock are issuable upon conversion of the Series B Preferred Stock as at March 31, 2020. Converted shares are rounded up to the nearest whole share. Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the "Series A Certificate of Designation") with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the "Series A Stated Value") and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 3). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company's common stock, and (ii) senior to the Company's Special Voting Preferred Stock and (iii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock shall be pari passu in liquidation to the Company's Series B Preferred Stock. The liquidation value of the Series A Preferred stock at March 31, 2020 and June 30, 2019 is the stated value of $278,530. There was no change to the Series A Preferred stock for the three or nine month periods ended March 31, 2020 or 2019. Common stock Stock Issuances Nine months ended March 31, 2020 Underwritten public offering On August 16, 2019, the Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), (ii) pre-funded warrants ("PFW") to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock ("2020 Investor Warrants"), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters' option to purchase additional securities, in the Company's underwritten public offering (the "Offering"). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant. The net proceeds from the Offering, including from the partial exercise of the underwriters' option to purchase additional securities, were $6,582,966, after deducting underwriting discounts and commissions, and other offering expenses. The 2020 Investor Warrants are exercisable at $1.00 per share until their expiry on August 16, 2024 and the PFW are exercisable at $0.01 per share at any time after August 16, 2019. The Company also issued 377,500 warrants to the underwriters of the Offering. The underwriter warrants are exercisable at $1.15 per share commencing February 10, 2020 until their expiry on August 14, 2022. During the nine months ended March 31, 2020, all of the 2,655,000 PFW were exercised at $0.01 per PFW for proceeds of $26,550. 2017 Omnibus Incentive Plan As approved by the Company's stockholders at the annual meeting of stockholders held on April 11, 2018, on July 7, 2017, as amended on February 1, 2018, the Company's board of directors approved adoption of the Company's 2017 Omnibus Equity Incentive Plan (the "2017 Plan"). The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units ("PSUs") under the 2017 Plan. Under the 2017 Plan, 780,000 shares of Company common stock are reserved for issuance, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the "Legacy Plan") or that are subject to grants of stock options made, or that may be made, under the Legacy Plan. A total of 164,235 shares of common stock have been issued under the Legacy Plan and/or are subject to outstanding stock options granted under the Legacy Plan, and a total of 614,515 shares of common stock have been issued under the 2017 Plan and/or are subject to outstanding stock options granted under the 2017 Plan leaving 1,250 shares of common stock available at March 31, 2020 for issuance under the 2017 Plan if all such options under the Legacy Plan were exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8% of the Company's fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on or after July 7, 2027, but awards granted prior to that date may extend beyond that date. During the nine months ended March 31, 2020, and subject to approval by the Company's stockholders, the Company's board of directors approved an increase in the number of shares of common stock available to be issued under the 2017 Plan by 1,500,000. The increase brings the total number of shares available under the 2017 Plan to 2,280,000. During the nine months ended March 31, 2020, the Company's board of directors approved an aggregate 1,041,016 stock options to officers and directors of the Company. Of the total grant, 549,199 stock options are subject to stockholder approval of the 2017 Plan share increase. The total grant date aggregate fair value of the remaining 491,817 stock options granted was $238,760. All of these stock options granted to officers and directors have an exercise price of $0.61 and expire on September 5, 2029. Of the 1,041,016 stock options approved by the board of directors, 375,000 vest pro rata monthly over one year from the date of approval by the board of directors and 666,016 vest as to one-sixth on the six-month anniversary of the date of approval by the board of directors with the remaining five-sixths vesting pro rate monthly over 30 months commencing on the seven-month anniversary of the board of directors' approval date. In addition, during the nine months ended March 31, 2020, the Company granted 250,000 stock options to an officer of the Company, subject to stockholder approval of the share increase to the 2017 Plan. The options have an exercise price of $0.735 and expire November 12, 2029. The options vest upon the achievement of certain clinical development milestones. Stock Options The following table sets forth the aggregate stock options outstanding under all plans as of March 31, 2020: Number of Weighted average outstanding $ Balance – June 30, 2019 288,183 22.31 Granted 491,817 0.61 Expired (1,250 ) (40.00 ) Balance – March 31, 2020 778,750 8.58 The following table summarizes stock options outstanding and exercisable under all plans at March 31, 2020: Exercise price Number Weighted Number 0.61 491,817 9.43 288,168 6.10 30,000 8.60 24,445 7.00 5,451 8.23 3,180 8.70 12,000 7.59 12,000 9.83 83,647 8.14 51,117 10.60 3,600 8.03 2,400 11.70 30,000 2.91 30,000 14.11 2,500 2.17 2,500 20.00 13,125 1.52 13,125 21.10 14,400 7.27 12,000 29.60 4,500 4.84 4,500 37.60 4,500 5.86 4,500 41.00 4,000 6.61 4,000 42.00 41,250 2.81 41,250 44.80 3,000 5.86 3,000 49.50 22,460 4.31 22,460 53.20 8,000 6.10 8,000 61.60 1,500 3.00 1,500 92.00 3,000 3.17 3,000 778,750 531,145 Included in the number of stock options outstanding are 2,500 stock options granted at an exercise price of CA $20.00. The exercise price of these options shown in the above table have been converted to US $14.11 using the period ending closing exchange rate. Stock options issued during the nine months ended March 31, 2020 have been valued using a Black-Scholes pricing model with the following assumptions: March 31, Dividend rate 0% Volatility 99% to 102% Risk-free rate 1.50% Term – years 5.5 to 6.5 The estimated volatility of the Company's common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the stock options at the valuation date. The expected life of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted: Three months ended Nine months ended 2020 2019 2020 2019 $ $ $ $ Research and development 22,754 12,889 55,058 64,466 General and administrative 73,437 86,846 251,970 290,922 96,191 99,735 307,028 355,388 All of the stock option expense for the periods ended March 31, 2020 and 2019 has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding at March 31, 2020 was $0 (2019 - $0) and the aggregate intrinsic value of stock options exercisable at March 31, 2020 was $0 (2019 - $0). As of March 31, 2020, there was $96,061 in unrecognized compensation expense that will be recognized over the next 2.43 years. No stock options granted under the Company's equity plans have been exercised during the nine months ended March 31, 2020. Upon the exercise of stock options new shares will be issued. The following table sets forth unvested stock options under all plans at March 31, 2020: Number of Weighted Weighted Unvested at June 30, 2019 84,990 11.35 5.82 Granted 491,817 0.61 0.40 Vested (329,202 ) 2.15 1.18 Unvested at March 31, 2020 247,605 2.25 1.23 Warrants The following table summarizes changes in the Company's outstanding warrants as of March 31, 2020: Description Number Balance – June 30, 2019 1,543,596 2020 Investor Warrants issued in underwritten offering 7,762,500 PFW issued in underwritten offering 2,655,000 2020 Underwriter Warrants 377,500 Exercise of PFW (2,655,000 ) Warrants issued for services (1) 530,000 Expiry of warrants for services (2) (4,140 ) Balance - March 31, 2020 10,209,456 (1) The Company issued 530,000 warrants for services during the nine months ended March 31, 2020. 280,000 warrants are exercisable at $0.75 per share until November 18, 2023 and they vest pro rata monthly commencing December 18, 2019. 250,000 warrants are exercisable at $0.64 per share until January 20, 2024 and they vest pro rata monthly commencing February 20, 2020. The total fair value of the warrants issued was $233,176 with $133,297 being recognized during the nine months ended March 31, 2020. (2) On February 27, 2020, 4,140 warrants at an exercise price of $59.30 expired. The following table summarizes the Company's outstanding warrants as of March 31, 2020: Description of warrants Number Exercise Expiry date 2020 Investor warrants 7,762,500 1.00 August 16, 2024 2019 Investor warrants 760,500 3.10 June 5, 2024 2018 Investor warrants 280,000 12.50 September 22, 2022 2017 Investor warrants 207,721 35.00 April 19, 2022 2015 Investor warrants 97,905 30.00 July 31, 2020 Warrants issued for services 250,000 0.64 January 20, 2024 Warrants issued for services 280,000 0.75 November 18, 2023 Warrants issued for services 26,500 30.00 July 1, 2020 to February 1, 2021 Warrants issued for services 6,000 17.80 January 25, 2023 Warrants issued for services 33,600 11.70 February 27, 2023 Warrants issued for services 12,000 9.00 September 15, 2023 Warrants issued for services 2,000 9.00 October 11, 2021 2020 Underwriter Warrants 377,500 1.15 August 14, 2022 2019 Agent warrants 46,800 3.875 June 3, 2024 2018 Agent warrants 40,000 12.50 September 20, 2022 2017 Agent warrants 13,848 40.60 April 12, 2022 2016 Agent warrants 10,402 40.00 May 12, 2021 2015 Agent warrants 2,180 30.00 July 15, 2020 10,209,456

Financial Instruments

Financial Instruments	9 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Financial instruments	6 Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: ● Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and ● Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company's financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Derivative liability The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company's own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a Black-Scholes Option Pricing Model (based on a closed-form model that uses a fixed equation) to estimate the fair value of the warrants which is equivalent to the fair value of the warrants calculated using the Binomial-Lattice Pricing Model. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities and volatility) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company's common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. a) Fair value of derivative liability The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher, or lower, as management estimates around specific probabilities change. The estimates may be significantly different from those amounts ultimately recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 3 financial instrument as volatility is considered a Level 3 input. The fair value of derivative liabilities at March 31, 2020 and June 30, 2019 was $0

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	9 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Supplementary statement of cash flows information	7 Supplementary statement of cash flows information Nine months ended March 31, 2020 2019 $ $ Series B Preferred share common stock dividend (note 5) 6,071 75,477 Income taxes paid - - Interest paid - -

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent events	8 Subsequent events The Company has evaluated its subsequent events from March 31, 2020 through the date these condensed consolidated financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated financial statements other than the items noted below. Subsequent to March 31, 2020, the Company issued 2,096 shares of common stock for services.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Reverse Stock Split	Reverse stock split On May 7, 2019, the Company filed a Certificate of Change with the Secretary of State of Nevada that effected a 1-for-10 (1:10) reverse stock split of its common stock, par value $0.001 per share, which became effective on May 8, 2019. Pursuant to the Certificate of Change, the Company's authorized common stock was decreased in the same proportion as the split resulting in a decrease from 70,000,000 authorized shares of common stock to 7,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these condensed consolidated interim financial statements give retroactive effect to the 1-for-10 reverse stock split. The Company's authorized and issued preferred stock was not affected by the split.
Amended articles of incorporation	Amended articles of incorporation On June 26, 2019, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 7,000,000 to 95,000,000 shares.
Basis of presentation	Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Del Mar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented.
Unaudited interim financial data	Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements of the Company as of, and for the fiscal year ended, June 30, 2019 included in the Form 10-K filed with the SEC on September 9, 2019. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three and nine months ended March 31, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2020, or for any other future annual or interim period.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.
Accruals for research and development expenses and clinical trials	Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company's objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company's clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the three and nine months ended March 31, 2020 and 2019, there were no material adjustments to the Company's prior period estimates of accrued expenses for clinical trials.
Loss per share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the three and nine month periods ended March 31, 2020 and 2019 diluted loss per share does not differ from basic loss per share since the effect of the Company's warrants, stock options, performance stock units, and convertible preferred shares is anti-dilutive. As of March 31, 2020, potential common shares of 10,209,456 (2019 – 862,502) related to outstanding warrants, 778,750 (2019 – 292,683) relating to stock options, nil (2019 – 120,000) relating to performance stock units, and 162,177 (2019 – 210,279) relating to outstanding Series B convertible preferred shares were excluded from the calculation of net loss per common share.
Recent accounting pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Recently adopted Accounting Standard Update ("ASU") 2016-02 — Leases (Topic 842) The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of ASU 2016-02 did not have a material impact on the Company's results of operations or financial results. ASU 2018-07 — Stock Compensation (Topic 718) Improvements to Nonemployee Shares-based Payment Accounting The amendments in this update are intended to the reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees. The ASU expands the scope of Topic 718, Compensation —Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to nonemployees for goods and services. The existing guidance on nonemployee share-based payments is significantly different from current guidance for employee share-based payments. This ASU expands the scope of the employee share-based payments guidance to include share-based payments issued to nonemployees. By doing so, the FASB improves the accounting of nonemployee share-based payments issued to acquire goods and services used in its own operations. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of ASU 2018-07 did not have a material impact on the Company's results of operations or financial results. Not yet adopted ASU 2017-11 — I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non-public Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception The amendments in this update are intended to reduce the complexity associated with the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the indefinite deferral of certain provisions of Topic 480 have been re-characterized to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company has not yet evaluated the impact of adoption of this ASU on its condensed consolidated interim financial statements and related disclosures. During the nine months ended March 31, 2020, other than ASU 2017-11, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company's condensed consolidated interim financial statements.

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative liabilities	Three months ended March 31, 2020 2019 $ $ Opening balance - 76 Change in fair value of warrants - 189 Closing balance - 265 Less current portion - - Long term portion - 265 Nine months ended March 31, 2020 2019 $ $ Opening balance - 1,117 Change in fair value of warrants - (852 ) Closing balance - 265 Less current portion - - Long term portion - 265

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Conversion of Series B Preferred stock to common stock	Series B Preferred Stock 2020 Number of shares $ Balance – June 30, 2019 673,613 4,699,304 Conversion of Series B Preferred stock to common stock (25,000 ) (174,407 ) Balance – March 31, 2020 648,613 4,524,897
Schedule of stock options outstanding	Number of Weighted average outstanding $ Balance – June 30, 2019 288,183 22.31 Granted 491,817 0.61 Expired (1,250 ) (40.00 ) Balance – March 31, 2020 778,750 8.58
Summary of stock options currently outstanding and exercisable	Exercise price Number Weighted Number 0.61 491,817 9.43 288,168 6.10 30,000 8.60 24,445 7.00 5,451 8.23 3,180 8.70 12,000 7.59 12,000 9.83 83,647 8.14 51,117 10.60 3,600 8.03 2,400 11.70 30,000 2.91 30,000 14.11 2,500 2.17 2,500 20.00 13,125 1.52 13,125 21.10 14,400 7.27 12,000 29.60 4,500 4.84 4,500 37.60 4,500 5.86 4,500 41.00 4,000 6.61 4,000 42.00 41,250 2.81 41,250 44.80 3,000 5.86 3,000 49.50 22,460 4.31 22,460 53.20 8,000 6.10 8,000 61.60 1,500 3.00 1,500 92.00 3,000 3.17 3,000 778,750 531,145
Schedule of valuation assumptions using a Black-Scholes pricing model	March 31, Dividend rate 0% Volatility 99% to 102% Risk-free rate 1.50% Term – years 5.5 to 6.5
Schedule of stock option expense	Three months ended Nine months ended 2020 2019 2020 2019 $ $ $ $ Research and development 22,754 12,889 55,058 64,466 General and administrative 73,437 86,846 251,970 290,922 96,191 99,735 307,028 355,388
Schedule of unvested stock options	Number of Weighted Weighted Unvested at June 30, 2019 84,990 11.35 5.82 Granted 491,817 0.61 0.40 Vested (329,202 ) 2.15 1.18 Unvested at March 31, 2020 247,605 2.25 1.23
Schedule of changes in outstanding warrants	Description Number Balance – June 30, 2019 1,543,596 2020 Investor Warrants issued in underwritten offering 7,762,500 PFW issued in underwritten offering 2,655,000 2020 Underwriter Warrants 377,500 Exercise of PFW (2,655,000 ) Warrants issued for services (1) 530,000 Expiry of warrants for services (2) (4,140 ) Balance - March 31, 2020 10,209,456 (1) The Company issued 530,000 warrants for services during the nine months ended March 31, 2020. 280,000 warrants are exercisable at $0.75 per share until November 18, 2023 and they vest pro rata monthly commencing December 18, 2019. 250,000 warrants are exercisable at $0.64 per share until January 20, 2024 and they vest pro rata monthly commencing February 20, 2020. The total fair value of the warrants issued was $233,176 with $133,297 being recognized during the nine months ended March 31, 2020. (2) On February 27, 2020, 4,140 warrants at an exercise price of $59.30 expired.
Schedule of outstanding warrants	Description of warrants Number Exercise Expiry date 2020 Investor warrants 7,762,500 1.00 August 16, 2024 2019 Investor warrants 760,500 3.10 June 5, 2024 2018 Investor warrants 280,000 12.50 September 22, 2022 2017 Investor warrants 207,721 35.00 April 19, 2022 2015 Investor warrants 97,905 30.00 July 31, 2020 Warrants issued for services 250,000 0.64 January 20, 2024 Warrants issued for services 280,000 0.75 November 18, 2023 Warrants issued for services 26,500 30.00 July 1, 2020 to February 1, 2021 Warrants issued for services 6,000 17.80 January 25, 2023 Warrants issued for services 33,600 11.70 February 27, 2023 Warrants issued for services 12,000 9.00 September 15, 2023 Warrants issued for services 2,000 9.00 October 11, 2021 2020 Underwriter Warrants 377,500 1.15 August 14, 2022 2019 Agent warrants 46,800 3.875 June 3, 2024 2018 Agent warrants 40,000 12.50 September 20, 2022 2017 Agent warrants 13,848 40.60 April 12, 2022 2016 Agent warrants 10,402 40.00 May 12, 2021 2015 Agent warrants 2,180 30.00 July 15, 2020 10,209,456

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	9 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of supplementary statement of cash flows information	Nine months ended March 31, 2020 2019 $ $ Series B Preferred share common stock dividend (note 5) 6,071 75,477 Income taxes paid - - Interest paid - -

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Nature of operations, corporate history, and going concern (Textual)
Net loss	$ (1,956,982)	$ (1,663,985)	$ (5,302,904)	$ (5,465,486)
Negative cash flow from operations			(5,348,629)	(4,514,674)
Accumulated deficit	(65,893,587)		(65,893,587)		$ (60,578,345)
Cash equivalents on hand	$ 4,973,378	$ 2,152,233	$ 4,973,378	$ 2,152,233	$ 3,718,758	$ 5,971,995

Significant Accounting Polici_3

Significant Accounting Policies (Details) - shares	May 07, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Jun. 26, 2019
Significant Accounting Policies (Textual)
Reverse stock split, description	Certificate of Change with the Secretary of State of Nevada that effected a 1-for-10 (1:10) reverse stock split of its common stock, par value $0.001 per share, which became effective on May 8, 2019.
Equity note stock split, description	Pursuant to the Certificate of Change, the Company's authorized common stock was decreased in the same proportion as the split resulting in a decrease from 70,000,000 authorized shares of common stock to 7,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these condensed consolidated interim financial statements give retroactive effect to the 1-for-10 reverse stock split. The Company's authorized and issued preferred stock was not affected by the split.
Common stock authorized		95,000,000		95,000,000
Series B Convertible Preferred Shares [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		162,177	210,279
Stock Options [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		778,750	292,683
Performance Stock Units [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding			120,000
Warrant [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		10,209,456	862,502
Common Stock [Member] | Minimum [Member]
Significant Accounting Policies (Textual)
Common stock authorized					7,000,000
Common Stock [Member] | Maximum [Member]
Significant Accounting Policies (Textual)
Common stock authorized					95,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019
Related party transactions (Textual)
Preferred stock, par value	$ 0.001		$ 0.001		$ 0.001
Dividend payable	$ 2,089	$ 2,089	$ 6,267	$ 6,267

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Summarized derivative liability
Opening balance		$ 76		$ 1,117
Change in fair value of warrants		189		(852)
Closing balance		265		265
Less current portion
Long term portion		$ 265		$ 265

Derivative Liability (Details T

Derivative Liability (Details Textual) - USD ($)	Mar. 31, 2020	Jun. 30, 2019
Derivative Liability (Textual)
Agent warrants, value	$ 2,180	$ 2,180
Derivative liabilities balance	$ 0	$ 0

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Mar. 31, 2020USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	$ 1,967,530
Ending Balance	3,720,486
Series B Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	$ 4,699,304
Beginning Balance, shares | shares	673,613
Conversion of Series B preferred stock to common stock	$ (174,407)
Conversion of Series B preferred stock to common stock, Shares | shares	(25,000)
Ending Balance	$ 4,524,897
Ending Balance, shares | shares	648,613

Stockholders' Equity (Details

Stockholders' Equity (Details 1)	9 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of stock options outstanding
Granted	491,817
Stock Options [Member]
Number of stock options outstanding
Beginning balance	288,183
Granted	491,817
Expired	(1,250)
Ending balance	778,750
Weighted average exercise price
Beginning balance | $ / shares	$ 22.31
Granted | $ / shares	0.61
Expired | $ / shares	(40)
Ending balance | $ / shares	$ 8.58

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Stock Options [Member] - $ / shares	9 Months Ended
	Mar. 31, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	778,750	288,183
Number exercisable	531,145
Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.61
Number of stock options outstanding	491,817
Weighted average remaining contractual life (years)	9 years 5 months 5 days
Number exercisable	288,168
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 6.10
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	8 years 7 months 6 days
Number exercisable	24,445
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 7
Number of stock options outstanding	5,451
Weighted average remaining contractual life (years)	8 years 2 months 23 days
Number exercisable	3,180
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 8.70
Number of stock options outstanding	12,000
Weighted average remaining contractual life (years)	7 years 7 months 2 days
Number exercisable	12,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 9.83
Number of stock options outstanding	83,647
Weighted average remaining contractual life (years)	8 years 1 month 20 days
Number exercisable	51,117
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 10.60
Number of stock options outstanding	3,600
Weighted average remaining contractual life (years)	8 years 11 days
Number exercisable	2,400
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 11.70
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	2 years 10 months 28 days
Number exercisable	30,000
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 14.11
Number of stock options outstanding	2,500
Weighted average remaining contractual life (years)	2 years 2 months 1 day
Number exercisable	2,500
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 20
Number of stock options outstanding	13,125
Weighted average remaining contractual life (years)	1 year 6 months 7 days
Number exercisable	13,125
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 21.10
Number of stock options outstanding	14,400
Weighted average remaining contractual life (years)	7 years 3 months 8 days
Number exercisable	12,000
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 29.60
Number of stock options outstanding	4,500
Weighted average remaining contractual life (years)	4 years 10 months 3 days
Number exercisable	4,500
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 37.60
Number of stock options outstanding	4,500
Weighted average remaining contractual life (years)	5 years 10 months 10 days
Number exercisable	4,500
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 41
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years)	6 years 7 months 10 days
Number exercisable	4,000
Exercise Price Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 42
Number of stock options outstanding	41,250
Weighted average remaining contractual life (years)	2 years 9 months 22 days
Number exercisable	41,250
Exercise Price Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 44.80
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	5 years 10 months 10 days
Number exercisable	3,000
Exercise Price Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 49.50
Number of stock options outstanding	22,460
Weighted average remaining contractual life (years)	4 years 3 months 22 days
Number exercisable	22,460
Exercise Price Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 53.20
Number of stock options outstanding	8,000
Weighted average remaining contractual life (years)	6 years 1 month 6 days
Number exercisable	8,000
Exercise Price Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 61.60
Number of stock options outstanding	1,500
Weighted average remaining contractual life (years)	3 years
Number exercisable	1,500
Exercise Price Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 92
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	3 years 2 months 1 day
Number exercisable	3,000

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Employee Stock Option [Member]	9 Months Ended
	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend rate	0.00%
Risk-free rate	1.50%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	99.00%
Term - years	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	102.00%
Term - years	6 years 6 months

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 96,191	$ 99,735	$ 307,028	$ 355,388
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	22,754	12,889	55,058	64,466
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 73,437	$ 86,846	$ 251,970	$ 290,922

Stockholders' Equity (Detail_2

Stockholders' Equity (Details 5)	9 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of stock options outstanding
Beginning balance | shares	84,990
Granted | shares	491,817
Vested | shares	(329,202)
Ending balance | shares	247,605
Weighted average exercise price
Beginning balance	$ 11.35
Granted	0.61
Vested	2.15
Ending balance	2.25
Weighted Average Grant Date Fair Value
Weighted average grant date fair value, Beginning balance	5.82
Weighted average grant date fair value, Granted	0.40
Weighted average grant date fair value, Vested	1.18
Weighted average grant date fair value, Ending balance	$ 1.23

Stockholders' Equity (Details 6

Stockholders' Equity (Details 6)	9 Months Ended
	Mar. 31, 2020shares
Summary of changes in outstanding warrants
Balance - December 31, 2019	250,000
Warrant [Member]
Summary of changes in outstanding warrants
Balance - June 30, 2019	1,543,596
2020 Investor Warrants issued in underwritten offering	7,762,500
PFW issued in underwritten offering	2,655,000
2020 Underwriter Warrants	377,500
Exercise of PFW	(2,655,000)
Warrants Issued for services	530,000	[1]
Expiry of warrants for services	(4,140)	[2]
Balance - December 31, 2019	10,209,456
[1]	The Company issued 530,000 warrants for services during the nine months ended March 31, 2020. 280,000 warrants are exercisable at $0.75 per share until November 18, 2023 and they vest pro rata monthly commencing December 18, 2019. 250,000 warrants are exercisable at $0.64 per share until January 20, 2024 and they vest pro rata monthly commencing February 20, 2020. The total fair value of the warrants issued was $233,176 with $133,297 being recognized during the nine months ended March 31, 2020.
[2]	On February 27, 2020, 4,140 warrants at an exercise price of $59.30 expired.

Stockholders' Equity (Details 7

Stockholders' Equity (Details 7) - $ / shares	9 Months Ended
	Mar. 31, 2020	Feb. 27, 2021	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	250,000
Exercise price	$ 0.64
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	10,209,456		1,543,596
Exercise price		$ 59.30
Warrants [Member] | Warrants issued for services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	250,000
Exercise price	$ 0.64
Expiry date	Jan. 20, 2024
Warrants [Member] | Warrants issued for services two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	26,500
Exercise price	$ 30
Expiry date	Nov. 18, 2023
Warrants [Member] | Warrants issued for services two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry date	Jul. 1, 2020
Warrants [Member] | Warrants issued for services two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry date	Feb. 1, 2021
Warrants [Member] | Warrants issued for services three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	6,000
Exercise price	$ 17.80
Expiry date	Jan. 25, 2023
Warrants [Member] | Warrants issued for services four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	33,600
Exercise price	$ 11.70
Expiry date	Feb. 27, 2023
Warrants [Member] | Warrants issued for services Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	12,000
Exercise price	$ 9
Expiry date	Sep. 15, 2023
Warrants [Member] | Warrants issued for services six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	2,000
Exercise price	$ 9
Expiry date	Oct. 11, 2021
Warrants [Member] | Warrants issued for services one [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	280,000
Exercise price	$ 0.75
2020 Investor Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	7,762,500
Exercise price	$ 1
Expiry date	Aug. 16, 2024
2019 Investor Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	760,500
Exercise price	$ 3.10
Expiry date	Jun. 5, 2024
2018 Investor Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	280,000
Exercise price	$ 12.50
Expiry date	Sep. 22, 2022
2017 Investor Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	207,721
Exercise price	$ 35
Expiry date	Apr. 19, 2022
2015 Investor Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	97,905
Exercise price	$ 30
Expiry date	Jul. 31, 2020
2020 Underwriter Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	377,500
Exercise price	$ 1.15
Expiry date	Aug. 14, 2022
2019 Agent Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	46,800
Exercise price	$ 3.875
Expiry date	Jun. 3, 2024
2018 Agent Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	40,000
Exercise price	$ 12.50
Expiry date	Sep. 20, 2022
2017 Agent Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	13,848
Exercise price	$ 40.60
Expiry date	Apr. 12, 2022
2016 Agent Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	10,402
Exercise price	$ 40
Expiry date	May 12, 2021
2015 Agent Warrants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	2,180
Exercise price	$ 30
Expiry date	Jul. 15, 2020

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 16, 2019	Sep. 30, 2014	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2016	Feb. 27, 2021	Jun. 30, 2019
Stockholders Equity Note [Line Items]
Preferred stock, par value			$ 0.001		$ 0.001				$ 0.001
Preferred stock, shares authorized			5,000,000		5,000,000				5,000,000
Preferred stock special voting shares issued			1		1				1
Common stock, shares authorized			95,000,000		95,000,000				95,000,000
Common stock, par value			$ 0.001		$ 0.001				$ 0.001
Common stock, shares issued (in shares)			11,427,132		11,427,132				3,839,358
Common stock issued under the 2017 Plan			1,250		1,250
Warrants are exercisable, per shares			$ 0.64		$ 0.64
Issued warrants to the underwriters			250,000		250,000
Proceeds from warrants exercised					$ 26,550	$ 726,179
Unvested stock options			247,605		247,605				84,990
Warrants exercise price			$ 0.64		$ 0.64
2017 Omnibus Incentive Plan [Member]
Stockholders Equity Note [Line Items]
Common stock, shares issued (in shares)			780,000		780,000
Common stock, shares outstanding			164,235		164,235
Common stock issued under the 2017 Plan			614,515		614,515
Percentage of fully diluted shares of common stock					8.00%
2017 Omnibus Incentive Plan [Member] | Board of Directors [Member]
Stockholders Equity Note [Line Items]
Legacy plan, description					The Company's board of directors approved an increase in the number of shares of common stock available to be issued under the 2017 Plan by 1,500,000. The increase brings the total number of shares available under the 2017 Plan to 2,280,000.
2017 Omnibus Incentive Plan [Member] | Officers and Directors [Member]
Stockholders Equity Note [Line Items]
Expiry date					Nov. 12, 2029
Legacy plan, description					The Company’s board of directors approved an aggregate 1,041,016 stock options to officers and directors of the Company. Of the total grant, 549,199 stock options are subject to stockholder approval of the 2017 Plan share increase. The total grant date aggregate fair value of the remaining 491,817 stock options granted was $238,760. All of these stock options granted to officers and directors have an exercise price of $0.61 and expire on September 5, 2029. Of the 1,041,016 stock options approved by the board for the grant, 375,000 vest pro rata monthly over one year from the date of approval by the board of directors and 666,016 vest as to one-sixth on the six-month anniversary of the date of approval by the board of directors with the remaining five-sixths vesting pro rate monthly over 30 months commencing on the seven-month anniversary of the board of directors approval date.
Employee Stock Option [Member]
Stockholders Equity Note [Line Items]
Stock options exercisable			531,145		531,145
Number of stock options outstanding			778,750		778,750				288,183
Aggregate intrinsic value of stock options outstanding			$ 0	$ 0	$ 0	0
Aggregate intrinsic value of stock options exercisable			0	$ 0	0	$ 0
Unrecognized compensation expense			$ 96,061		$ 96,061
Unrecognized compensation expense, term					2 years 5 months 5 days
Employee Stock Option [Member] | CA$ $20.00 Exercise Price [Member]
Stockholders Equity Note [Line Items]
Stock options exercise price			$ 14.11		$ 14.11
Number of stock options outstanding			2,500		2,500
Pre Funded Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants are exercisable, per shares			$ 0.01		$ 0.01
Issued warrants to the underwriters			2,655,000		2,655,000
Proceeds from warrants exercised					$ 26,550
Warrants exercise price			$ 0.01		$ 0.01
Warrant [Member]
Stockholders Equity Note [Line Items]
Warrants are exercisable, per shares								$ 59.30
Issued warrants to the underwriters			10,209,456		10,209,456				1,543,596
Warrants, description					The Company issued 530,000 warrants for services during the nine months ended March 31, 2020. 280,000 warrants are exercisable at $0.75 per share until November 18, 2023 and they vest pro rata monthly commencing December 18, 2019. 250,000 warrants are exercisable at $0.64 per share until January 20, 2024 and they vest pro rata monthly commencing February 20, 2020. The total fair value of the warrants issued was $233,176 with $133,297 being recognized during the nine months ended March 31, 2020.
Number of warrants								4,140
Warrants exercise price								$ 59.30
Stock Optionst [Member]
Stockholders Equity Note [Line Items]
Legacy plan, description					Stock Options
2020 Investor Warrant [Member]
Stockholders Equity Note [Line Items]
Underwritten public offering, description	The Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), (ii) pre-funded warrants ("PFW") to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock ("2020 Investor Warrants"), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters' option to purchase additional securities, in the Company's underwritten public offering (the "Offering"). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.
Underwriting discounts and commissions amount	$ 6,582,966
Warrants are exercisable, per shares	$ 1
Expiry date	Aug. 16, 2024
Warrants exercise price	$ 1
2020 Investor Warrant [Member] | Underwriting Offering [Member]
Stockholders Equity Note [Line Items]
Warrants are exercisable, per shares	$ 1.15
Expiry date	Aug. 14, 2022
Underwriter warrants commencing date	Feb. 10, 2020
Issued warrants to the underwriters	377,500
Warrants exercise price	$ 1.15
2020 Investor Warrant [Member] | Pre Funded Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants are exercisable, per shares	$ 0.01
Expiry date	Aug. 16, 2019
Warrants exercise price	$ 0.01
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued			648,613		648,613				673,613
Preferred stock, shares outstanding			648,613		648,613				673,613
Preferred stock, rate of dividend							9.00%
Purchase price of shares							$ 80
Convertible preferred stock							0.25
Conversion price							$ 32
Conversion of series B preferred stock to common stock, shares			3,700	4,735	11,100	14,430
Issue of shares							902,238
Bid price							$ 8
Final closing date							5 years
Direct increase in accumulated deficit			$ 1,473	$ 23,202	$ 6,071	$ 75,477
Common stock are issuable upon conversion					162,177	210,279
Liquidation value			$ 5,188,904		$ 5,188,904				$ 5,388,904
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued			278,530		278,530				278,530
Preferred stock, shares outstanding			278,530		278,530				278,530
Liquidation value			$ 278,530		$ 278,530				$ 278,530
Series A Preferred Stock [Member] | Exchange Agreement [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value		$ 1
Preferred stock, shares issued		278,530
Preferred stock, rate of dividend		3.00%

Financial Instruments (Details)

Financial Instruments (Details) - USD ($)	Mar. 31, 2020	Jun. 30, 2019
Financial Instruments
Fair value of derivative liabilities	$ 0	$ 0

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information (Details) - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Supplemental Cash Flow Information [Abstract]
Series B Preferred share common stock dividend (note 5)	$ 6,071	$ 75,477
Income taxes paid
Interest paid

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Apr. 30, 2020shares
Subsequent Event [Member]
Subsequent Events (Textual)
Shares issued of common stock for services	2,096